Last Updated : April 25, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Cosentyx | secukinumab | Hidradenitis suppurativa | Suspended | |||
| Cosentyx | Secukinumab | Plaque psoriasis | List with criteria/condition | Complete | ||
| Cosentyx | Secukinumab | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cosentyx | Secukinumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Corzyna | ranolazine | Stable angina pectoris, adults | Do not reimburse | Complete | ||
| Cortiment | Budesonide | Ulcerative Colitis | Do not reimburse | Complete | ||
| Copaxone | Glatiramer acetate | Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis | Do not list | Complete | ||
| Contrave | naltrexone hydrochloride and bupropion hydrochloride | Chronic weight management in adults | Do not reimburse | Complete | ||
| Constella | Linaclotide | Irritable bowel syndrome with constipation | Do not list | Complete | ||
| COMPLERA | Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate | HIV infection | List | Complete |
Last Updated : April 25, 2024